EGFR and lung adenocarcinoma: Patients with lung adenocarcinoma harboring the EGFR S768I and G724S mutations appear less sensitive to first‐generation tyrosine kinase inhibitors than patients with sensitive EGFR.However, the patient benefited from treatment with afatinib.